Filter Results:
- Full text PDF available (79)
Publication Year
1996
2018
- This year (41)
- Last 5 years (221)
- Last 10 years (294)
Publication Type
Co-author
Journals and Conferences
Learn More
- Martin Peifer, Lynnette Fernández-Cuesta, +90 authors Roman K. Thomas
- Nature Genetics
- 2012
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis. We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an extremely high mutation rate of 7.4 ±… (More)
- Emma Pailler, Julien Adam, +11 authors Françoise Farace
- Journal of clinical oncology : official journal…
- 2013
PURPOSE
The diagnostic test for ALK rearrangement in non-small-cell lung cancer (NSCLC) for crizotinib treatment is currently done on tumor biopsies or fine-needle aspirations. We evaluated whether… (More)
- Bertrand Routy, Emmanuelle Le Chatelier, +45 authors Laurence Zitvogel
- Science
- 2018
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be… (More)
- Jean-Marie Michot, Camille Bigenwald, +21 authors Olivier Lambotte
- European journal of cancer
- 2016
Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new… (More)
- Maria Vittoria Dieci, Monica Arnedos, Fabrice Andre, Jean – Charles Soria
- Cancer discovery
- 2013
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiologic processes, including embryogenesis, adult tissue homeostasis,… (More)
- Jean – Charles Soria, E Felip, +15 authors Glenwood D Goss
- The Lancet. Oncology
- 2015
BACKGROUND
There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib… (More)
- Fabrice Barlési, Julien Mazières, +29 authors Gérard Zalcman
- The Lancet
- 2016
BACKGROUND
The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility… (More)
- Jean – Charles Soria, Yi-Long Wu, +16 authors Tony Shu Kam Mok
- The Lancet. Oncology
- 2015
BACKGROUND
Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess… (More)
- Françoise Farace, Christophe C Massard, +12 authors Philippe Vielh
- British Journal of Cancer
- 2011
Background:Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we… (More)
- Hassane Izzedine, Christophe C Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean – Charles Soria
- European journal of cancer
- 2010
Proteinuria is a dose-related side-effect occurring after inhibition of vascular endothelial growth factor (VEGF) signalling and may reflect severe glomerular damage. The inhibition of the VEGF… (More)